Abeona Therapeutics Engages Investors at Upcoming Conferences
Abeona Therapeutics Inc. (NASDAQ: ABEO) is thrilled to announce several opportunities for investor engagement at various conferences this September. The management team is eager to highlight the latest advancements in their pioneering gene and cell therapies that aim to meet significant unmet medical needs.
Details of the Conferences
The first event on the calendar is the Wells Fargo Healthcare Conference, where Abeona will conduct investor meetings on September 5. This conference will provide investors with an in-depth look at the company's ongoing initiatives and future plans.
Next up is the H.C. Wainwright Annual Global Investment Conference, scheduled for September 10. Abeona will deliver a company presentation at 1:30 p.m. ET, along with additional investor meetings. This event presents an excellent opportunity for Abeona to share its progress and vision with committed stakeholders.
Lastly, the Cantor Global Healthcare Conference will take place on September 19. Abeona will participate in a fireside chat at 9:45 a.m. ET, along with investor meetings, giving attendees a chance to gain deeper insights into the company's strategic direction.
Abeona's Innovative Approach to Medicine
Abeona Therapeutics is leading the way in the development of transformative therapies through its cutting-edge gene and cell technology. Their flagship product, Prademagene zamikeracel (pz-cel), is designed to treat severe conditions such as recessive dystrophic epidermolysis bullosa. The company takes pride in its integrated manufacturing facilities, which are essential for producing pz-cel for clinical trials and will support commercial production once FDA approval is obtained.
In addition, Abeona is dedicated to creating AAV-based gene therapies aimed at treating ophthalmic diseases, which pose significant treatment challenges. The research team is actively working on next-generation AAV capsids that not only improve delivery mechanisms within the body but also strive to enhance treatment outcomes for patients affected by these conditions.
Connect with Abeona Therapeutics
Those interested in following Abeona's progress can visit the company's website to access live webcasts of these important presentations and explore the content available in the Investors section. This platform will also provide replays of the conference details for future reference, ensuring that stakeholders can stay updated.
Frequently Asked Questions
What conferences will Abeona Therapeutics participate in this September?
Abeona Therapeutics will participate in the Wells Fargo Healthcare Conference on September 5, the H.C. Wainwright Annual Global Investment Conference on September 10, and the Cantor Global Healthcare Conference on September 19.
What is the focus of Abeona’s research and development?
Abeona specializes in developing cell and gene therapies to treat serious diseases, particularly focusing on conditions like recessive dystrophic epidermolysis bullosa and various ophthalmic diseases.
How can investors access Abeona's conference presentations?
Investors can access the live webcasts of Abeona's conference presentations through the Investors section of their website, where recordings will also be available for a limited time.
What is Prademagene zamikeracel (pz-cel)?
Pz-cel is an investigational therapy developed by Abeona, specifically targeting recessive dystrophic epidermolysis bullosa by using gene-corrected epidermal sheets.
Where can I find more information about Abeona Therapeutics?
For more information, visit Abeona's official website, which provides comprehensive details about their therapies, company news, and upcoming events.
